{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=4",
    "query": {
      "condition": "Advanced Gastrointestinal Malignancies",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 2243,
    "total_pages": 225,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Gastrointestinal+Malignancies&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:48:01.079Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05678257",
      "title": "A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Adenocarcinoma",
        "Colorectal Cancer Metastatic",
        "Neoplasm, Colorectal"
      ],
      "interventions": [
        {
          "name": "Fosifloxuridine Nafalbenamide",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NuCana plc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2023-04-18",
      "completion_date": "2024-08-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 16,
      "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Gainesville, Florida + 12 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05678257"
    },
    {
      "nct_id": "NCT04798781",
      "title": "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Telatinib",
          "type": "DRUG"
        },
        {
          "name": "Keytruda",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Hendifar, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-07-28",
      "completion_date": "2025-10-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Los Angeles, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798781"
    },
    {
      "nct_id": "NCT01181245",
      "title": "A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "FG-3019",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-12",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-06",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Lebanon, New Hampshire • Cleveland, Ohio + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181245"
    },
    {
      "nct_id": "NCT03653507",
      "title": "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer",
        "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "zolbetuximab",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 507,
      "start_date": "2018-11-28",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 11,
      "location_summary": "Monterey, California • Fairway, Kansas • New Orleans, Louisiana + 7 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03653507"
    },
    {
      "nct_id": "NCT07227012",
      "title": "Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Hepatocellular Cancer",
        "Hepatocellular Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Liver Neoplasms",
        "Advanced Hepatocellular Carcinoma",
        "Metastatic Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2025-12-01",
      "completion_date": "2028-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 46,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227012"
    },
    {
      "nct_id": "NCT00923481",
      "title": "A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Pheochromocytoma",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Fostamatinib disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2009-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-09-30",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923481"
    },
    {
      "nct_id": "NCT01959672",
      "title": "Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Resectable Pancreatic Carcinoma",
        "Stage I Pancreatic Cancer",
        "Stage IA Pancreatic Cancer",
        "Stage IB Pancreatic Cancer",
        "Stage II Pancreatic Cancer",
        "Stage IIA Pancreatic Cancer",
        "Stage IIB Pancreatic Cancer",
        "Stage III Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "4-Dimensional Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-09-06",
      "completion_date": "2018-12-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959672"
    },
    {
      "nct_id": "NCT03071757",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-368",
          "type": "DRUG"
        },
        {
          "name": "ABBV-181",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2017-03-21",
      "completion_date": "2022-04-13",
      "has_results": false,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071757"
    },
    {
      "nct_id": "NCT01402401",
      "title": "Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "AUY922",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-11",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Lake Success, New York • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01402401"
    },
    {
      "nct_id": "NCT02494037",
      "title": "The Canadian/US Integrative Oncology Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Neoplasms",
        "Colorectal Neoplasms",
        "Pancreatic Neoplasms",
        "Ovarian Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Canadian College of Naturopathic Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2015-01-01",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-11-19T01:48:01.079Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Kailua, Hawaii • Fife, Washington + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Kailua",
          "state": "Hawaii"
        },
        {
          "city": "Fife",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02494037"
    }
  ]
}